Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January

Celcuity Inc. (NASDAQ:CELC) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,330,000 shares, an increase of 6.4% from the January 15th total of 3,130,000 shares. Based on an average trading volume of 283,600 shares, the short-interest ratio is currently 11.7 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Needham & Company LLC increased their price objective on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $30.17.

Celcuity Stock Down 0.9 %

NASDAQ:CELC traded down $0.12 during trading hours on Tuesday, hitting $12.76. The stock had a trading volume of 230,522 shares, compared to its average volume of 229,775. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity has a 1-year low of $10.35 and a 1-year high of $22.19. The business has a 50 day simple moving average of $12.26 and a two-hundred day simple moving average of $14.10. The company has a market cap of $473.78 million, a PE ratio of -4.89 and a beta of 0.73.

Institutional Trading of Celcuity

Several large investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Celcuity during the third quarter worth approximately $119,000. nVerses Capital LLC acquired a new stake in shares of Celcuity during the third quarter worth approximately $33,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Celcuity by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 73,026 shares of the company’s stock worth $1,089,000 after buying an additional 18,809 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Celcuity during the third quarter worth approximately $86,000. Finally, Quest Partners LLC grew its position in shares of Celcuity by 227.6% during the third quarter. Quest Partners LLC now owns 18,962 shares of the company’s stock worth $283,000 after buying an additional 13,174 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.